MedTrace Logo

the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19

NCT04521400 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-08-20

No results posted yet for this study

Summary

The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

Conditions

  • Covid19

Interventions

DRUG

High dose Interferon-beta 1a

High dose IFN-β1a (Recigen) (Subcutaneous injections of 88μg (24,000 IU) on days 1, 3, 6)

DRUG

Lopinavir/Ritonavir

Lopinavir/Ritonavir (Kaletra) \[IFN-β1a group\] (400mg/100 mg twice a day for 10 days

DRUG

Low dose Interferon-beta 1a

Low doseIFN-β1a (Recigen) (Subcutaneous injections of 44μg (12,000 IU) on days 1, 3, 6)

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Ilad Alavi Darazam, M.D · Shahid Beheshti University of Medical Sciences

  • Firouze Hatami, M.D · Shahid Beheshti University of Medical Sciences

  • Mohammad Mahdi Rabiei, M.D · Shahid Beheshti University of Medical Sciences

  • Omid Moradi · Shahid Beheshti University of Medical Sciences

  • Behnam Rahimi, M.D · Shahid Beheshti University of Medical Sciences

  • Shervin Shokouhi, M.D · Shahid Beheshti University of Medical Sciences

  • Mohammad Reza Hajesmaeili, M.D · Shahid Beheshti University of Medical Sciences

  • Minoosh Shabani, M.D · Shahid Beheshti University of Medical Sciences

  • Seyed Sina Naghibi Irvani, M.D · Shahid Beheshti University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-20
Primary Completion
2020-09-04
Completion
2020-09-11

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04521400 on ClinicalTrials.gov